Clinical Trials in Dresden, Germany

428 recruiting

Showing 120 of 490 trials

Recruiting
Phase 3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Plaque Psoriasis
Bristol-Myers Squibb3,040 enrolled383 locationsNCT07116967
Recruiting
Phase 1Phase 2

Study for AZD4360 in Participants With Advanced Solid Tumours

Gastric CancerGastroesophageal-junction CancerBiliary Tract Cancer+1 more
AstraZeneca117 enrolled18 locationsNCT06921928
Recruiting
Phase 1Phase 2

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals123 enrolled19 locationsNCT07226986
Recruiting
Phase 3

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

Heart Failure
Boehringer Ingelheim6,000 enrolled652 locationsNCT06424288
Recruiting
Phase 2

Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

T-ALL
Goethe University40 enrolled15 locationsNCT06648889
Recruiting
Phase 3

STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant
University of Cologne420 enrolled30 locationsNCT07280585
Recruiting
Phase 3

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma
AstraZeneca1,220 enrolled220 locationsNCT06921785
Recruiting
Phase 3

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)
Regeneron Pharmaceuticals904 enrolled155 locationsNCT06091865
Recruiting
Phase 2

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis
Corcept Therapeutics279 enrolled35 locationsNCT05407324
Recruiting
Phase 3

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Renal Cell Carcinoma
Merck Sharp & Dohme LLC904 enrolled111 locationsNCT07227402
Recruiting
Phase 3

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC815 enrolled119 locationsNCT07218029
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
UCB Biopharma SRL450 enrolled230 locationsNCT06617325
Recruiting
Phase 3

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Essential Thrombocythemia
Merck Sharp & Dohme LLC340 enrolled163 locationsNCT06079879
Recruiting
Phase 3

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Biliary Tract Cancer
AstraZeneca620 enrolled270 locationsNCT06467357
Recruiting
Phase 3

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,630 enrolled261 locationsNCT07213804
Recruiting

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb1,700 enrolled99 locationsNCT05489705
Recruiting

PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

Breast CancerBreast NeoplasmsNeoplasm Metastasis
AstraZeneca800 enrolled107 locationsNCT05573893
Recruiting
Phase 1Phase 2

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC298 enrolled43 locationsNCT06780111
Recruiting
Phase 2

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 3

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled192 locationsNCT06982521